Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma.

OBJECTIVE Free radical-induced oxidative stress with consequent lipid peroxidation and resultant tissue damage has been suggested as a potential mechanism of the pathogenesis of scleroderma. However, because reliable measurement of lipid peroxidation in vivo is difficult, it has not been possible to adequately examine this hypothesis. We have previously described a series of bioactive prostaglandin F2-like compounds, termed F2-isoprostanes, produced in vivo in humans by the non-cyclooxygenase, free radical-catalyzed, peroxidation of arachidonic acid and have shown them to be a reliable measure of lipid peroxidation in vivo. In the present study, we determined whether scleroderma is associated with enhanced oxidative stress. METHODS As a measure of oxidative stress, we determined urinary concentrations of a tetranor-dicarboxylic acid metabolite of F2-isoprostanes (F2IP-M) by mass spectrometry in 8 patients with scleroderma (representing a wide spectrum of disease, including limited disease with refractory digital ulceration or pulmonary hypertension, and diffuse disease) and in 10 healthy control subjects. RESULTS F2IP-M concentrations were significantly higher in patients with scleroderma (mean +/- SEM 3.41 +/- 0.64 ng/mg of creatinine) than in healthy controls (1.22 +/- 0.14 ng/mg of creatinine) (P = 0.002). These elevations occurred in patients with limited disease and in those with diffuse disease. CONCLUSION The increased level of urinary F2IP-M supports the hypothesis that free radical-induced oxidative injury occurs in scleroderma and provides a biologic marker whose relationship to disease activity and disease therapy may be important. These findings may also provide a rationale for exploring whether antioxidant therapy may influence the natural course of the disease.

[1]  C. Black,et al.  Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. , 1995, Arthritis and rheumatism.

[2]  J. Morrow,et al.  Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. , 1995, The New England journal of medicine.

[3]  B. Halliwell,et al.  Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? , 1994, The Lancet.

[4]  J. Morrow,et al.  Cyclosporine-induced alterations in renal function are not associated with lipid peroxidation. , 1994, Transplantation.

[5]  J. Morrow,et al.  Evidence that the F2-isoprostane, 8-epi-prostaglandin F2α, is formed in vivo , 1994 .

[6]  J. Morrow,et al.  Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome. , 1993, Journal of lipid mediators.

[7]  J. Morrow,et al.  Improved assay for the quantification of 11-dehydrothromboxane B2 by gas chromatography-mass spectrometry. , 1993, Journal of chromatography.

[8]  J. Morrow,et al.  Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. , 1993, The Journal of biological chemistry.

[9]  D. Murrell A radical proposal for the pathogenesis of scleroderma. , 1993, Journal of the American Academy of Dermatology.

[10]  J. Morrow,et al.  Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. , 1992, The Journal of clinical investigation.

[11]  S. Orlow Cutaneous findings in craniofacial malformation syndromes. , 1992, Archives of dermatology.

[12]  J. Catravas,et al.  Methylene blue inhibits nitrovasodilator- and endothelium-derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells via generation of superoxide anion. , 1992, The Journal of pharmacology and experimental therapeutics.

[13]  A. L. Goldin,et al.  Protein kinase A phosphorylation enhances sodium channel currents in Xenopus oocytes. , 1992, The American journal of physiology.

[14]  C. Lau,et al.  Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon. , 1992, British journal of rheumatology.

[15]  U. Das,et al.  Reactive oxygen species, lipid peroxides and essential fatty acids in patients with rheumatoid arthritis and systemic lupus erythematosus. , 1991, Prostaglandins, leukotrienes, and essential fatty acids.

[16]  J. Morrow,et al.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[17]  B. Halliwell,et al.  The measurement and mechanism of lipid peroxidation in biological systems. , 1990, Trends in biochemical sciences.

[18]  G. Murrell,et al.  Modulation of fibroblast proliferation by oxygen free radicals , 1990 .

[19]  A. Bast,et al.  Oxygen radicals in lung pathology. , 1990, Free radical biology & medicine.

[20]  J. Morrow,et al.  Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. , 1990, Analytical biochemistry.

[21]  M. Hecker,et al.  On the mechanism of prostacyclin and thromboxane A2 biosynthesis. , 1989, The Journal of biological chemistry.

[22]  T. Medsger,et al.  Cutaneous hypoxia in patients with systemic sclerosis (scleroderma). , 1988, Archives of dermatology.

[23]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[24]  B. Halliwell,et al.  The measurement of free radical reactions in humans , 1987, FEBS letters.

[25]  G. FitzGerald,et al.  Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. , 1986, British medical journal.

[26]  A. Masi Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[27]  G. Rodnan,et al.  Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. , 1980, Medicine.